Strategy
The Paris-based group is paying €350m upfront to get hold of Marseille-headquartered ImCheck's acute myeloid leukemia candidate.
Bharat Serums showed it’s possible to score a regulatory win with real-world evidence (RWE) studies in India when it ran one leading to a label expansion for its mAb trinbelimab. As cell and gene therapies and rare disease drugs gain currency, sponsors could look at takeaways from the RhYTHM study.
Galapagos is closing its cell therapy business after a prolonged search for buyers, leading to job cuts and site closures in the US, Netherlands, Switzerland and China.
Drug development in China was a discussion topic at the BioFuture conference as the country’s R&D investments begin to deliver first-in-class medicines.
Despite announcing sales growth that is currently weathering the storm of one of its biggest losses of exclusivity and a spin-off of its orthopedic division, J&J’s stock price weakened after its earnings announcement. Investors probably wanted more visibility on MFN.
Faeth Therapeutics raised $25m to complete a Phase II trial of its PIK3/mTOR-targeting drug combination in endometrial cancer and reported positive Phase II data at ESMO in ovarian cancer with half of the combo.
Seeking to compete with GSK’s Benlysta, the Roche unit obtains the first FDA approval of an anti-CD20 agent in lupus nephritis, a complication of lupus that can lead to end-stage kidney disease.
The company breaks new ground with Keytruda for platinum-resistant ovarian cancer and unveils promising Phase II data on its Daiichi-Sankyo-partnered ADC raludotatug deruxtecan.
Positive data from the PSMAddition trial potentially doubles the number of prostate cancer patients eligible for treatment with the Swiss major’s big-selling radioligand therapy but a discussant at ESMO was not convinced by the study.
Plus deals involving Astellas/Taysha, Haihe/Taiho, AimedBio/Boehringer Ingelheim, Takeda/Nabla, CytoMed/TC BioPharm, Specialised Therapeutics/CanariaBio, UgeneX/AviadoBio, Lupin, Kissei/Searchlight, Kazia/QIMR and Prism/Servier.
The vocal shareholder tells Scrip that other investors have reached out supporting its push for a sale of the vaccine maker.
Drug makers are reevaluating commercial opportunities outside the US in a post-MFN environment, according to experts at the BioFuture conference
Adcytherix and Step Pharma join Tubulis in raising funds for their cancer drug projects.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
Omeros suspended a Phase III program for zaltenibart in May due to financial limitations, but will now get $240m up front from Novo Nordisk for the PNH candidate.
With an improving outlook for deals, experts at the BioFuture conference discussed what needs big pharma has and what type of deals to expect.
Deal Snapshot: BioCryst is buying Astria in a cash-and-stock deal to get hold of the latter's late-stage injectable hereditary angioedema drug, navenibart, which promises less frequent dosing than Takeda’s market leading injection Takhzyro.
The largest financing for a private ADC developer globally will help the German biotech advance its two clinical- stage ADC candidates.
Activist investor Shah Capital, Novavax’s second-largest shareholder, has again questioned why the vaccine maker has not captured more market share despite widespread anti-mRNA sentiment.
Following Pfizer and AstraZeneca’s US drug-pricing deals with the Trump Administration, the CEO said J&J continually has sought common ground with the White House.